title: [Cardiovascular risk in systemic inflammatory diseases].
abstract: Systemic inflammatory diseases are associated with increased cardiovascular morbidity and mortality. The link between inflammatory and cardiovascular diseases can be attributed to the coexistence of classical risk factors and inflammatory mechanisms activated during systemic inflammatory diseases involving the immune system. Unfavorable metabolic effects of anti-inflammatory drugs can also contribute to increase cardiovascular risk. Yet, clinical implications of these findings are not entirely clear, and deeper knowledge and awareness of cardiac involvement in inflammatory diseases are necessary. The aim of this review is to summarize cardiac involvement in systemic inflammatory diseases and to identify aspects where evidence is currently lacking that would deserve further investigation in the future.
authors.affiliation: Dipartimento di Scienze Biomediche Avanzate, Università degli Studi Federico II, Napoli, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Marsico
authors.forename: Antonio
authors.initials: A
authors.lastname: Parente
authors.forename: Stefania
authors.initials: S
authors.lastname: Paolillo
authors.forename: Laura
authors.initials: L
authors.lastname: Casaretti
authors.forename: Francesco
authors.initials: F
authors.lastname: Lo Iudice
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Pirozzi
authors.forename: Sirio
authors.initials: S
authors.lastname: Conte
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Iardino
authors.forename: Francesco
authors.initials: F
authors.lastname: Gambardella
authors.forename: Giuseppe Luca
authors.initials: GL
authors.lastname: Della Ratta
authors.forename: Annapaola
authors.initials: A
authors.lastname: Cirillo
authors.forename: Alice
authors.initials: A
authors.lastname: Vitagliano
authors.forename: Pasquale Perrone
authors.initials: PP
authors.lastname: Filardi
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D003327:Coronary Disease / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha